Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: lwd who wrote (591)	1/6/1998 7:16:00 PM
From: Bill Holtzman	Respond to of 1728

I'm looking at the chart and seeing a descending triangle. The book says this will likely end in a breakout down to around 20 over the next month or two. Any comments? Bill

To: lwd who wrote (591)	1/7/1998 1:28:00 AM
From: Angelo Ferraro	Respond to of 1728

Affymetrix sues Synteni, Incyte over patent ========================================= this may be of interest, Angelo ================================================== at: biz.yahoo.com SANTA CLARA, Calif., Jan 6 (Reuters) - Affymetrix Inc (Nasdaq:AFFX - news) said Tuesday it was suing Synteni Inc and Incyte Pharmaceuticals Inc (Nasdaq:INCY - news) for alleged infringement of an Affymetrix patent involving its GeneChip technology. In a statement, Affymetrix said the patent at issue, U.S. Patent No. 5,445,934, is part of its more than 25 issued U.S. patents and more than 70 pending applications which cover various aspects of its GeneChip technology. Its GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyse and manage genetic information. Synteni and Incyte could not be reached for comment. The patent which was allegedly infringed covers arrays of 1,000 or more different pieces of DNA in a square centimetre of area. Affymetrix said it filed the suit with the federal district court in Delaware. Palo Alto, California-based Incyte is named in the suit as it recently agreed to acquire Synteni and announced its intention to commercialise Synteni's spotted DNA arrays for monitoring of gene expression, Affymetrix said. ''Affymetrix and Incyte have been both good partners and good competitors for some time now, and we remain hopeful that we will reach an agreement with Incyte that provides fair compensation to Affymetrix for the use of our intellectual property,'' said Stephen P.A. Fodor, Affymetrix' president and chief executive officer. Fremont, California-based Synteni makes technology for analysing large numbers of genes in a single experiment. Incyte makes databases of all the latest research into the human genome. Affymetrix said that gene expression monitoring is one of three major areas of application of its GeneChip technology. It has a program to license its technology for use in making low to medium density spotted arrays for expression monitoring and has one such licence with Molecular Dynamics (Nasdaq:MDYN - news). It currently has a joint venture with Incyte to commercialise five licence Affymetrix arrays in the expression monitoring field. Affymetrix said it intends to make its GeneChip system the ''platform of choice'' for acquiring, analysing and managing complex genetic information in order to improve the diagnosis, monitoring and treatment of disease.

To: lwd who wrote (591)	1/7/1998 3:41:00 PM
From: Boyce Burge	Read Replies (1) \| Respond to of 1728

lwl, heres a reference for you for Aurora... the mechanism requires a little reading to understand, and isnt very well explained on their web site. Read the Science article.... Company Press Release Aurora Biosciences Announces Publication In Science Of Novel Fluorescence Assay Technology SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 1998--Aurora Biosciences Corp. (NASDAQ:ABSC - news) Wednesday announced the publication in Science, Vol. 279, Jan. 2, 1998, of an article titled ''Quantitation of Transcription and Clonal Selection of Single Living Cells with beta-Lactamase as Reporter.'' The first author is Gregor Zlokarnik, Ph.D., principal chemist at Aurora; five other authors are Aurora scientists, and the senior author is Roger Y. Tsien, Ph.D., a Howard Hughes Medical Institute investigator, professor of Pharmacology, Chemistry and Biochemistry at the University of California San Diego, and scientific advisor to Aurora. The initial development of the beta-lactamase reporter system was conducted in Dr. Tsien's laboratory at UCSD, and Aurora has an exclusive license to this technology from the Regents of the University of California. The beta-lactamase reporter system is an advance over existing, well-established reporter genes, such as chloramphenicol acetyltransferase or luciferase, because it provides extremely sensitive readouts from single living human cells. Many important genes are expressed only at low levels and can be difficult or impossible to study with previous reporters. Changes in gene expression can be visualized by a change from green to blue fluorescence in the living cell. The authors of the Science paper point out that the beta-lactamase reporter system will facilitate many applications including expression cloning of genes that can modulate transcription, functional genomics in human cells by gene trapping, and creating cell-based screenings for novel pharmaceutical targets. ''We are delighted that one of Aurora's proprietary fluorescent assay technologies has been considered an important enough advance to merit publication in Science and to provide the illustration for the front cover of the first issue of the journal in 1998,'' commented J. Gordon Foulkes, Ph.D., Aurora's chief technical officer. ''Previous reporter gene systems have been important tools in cell biology, and in pharmaceutical drug discovery. An ability with this new reporter to rapidly isolate a few living cells expressing a particular gene from millions of cells (clonal selection) is a significant advance. The beta-lactamase system also enables rapid incorporation of newly discovered genes into cell-based assays for high-throughput screening of several important classes of drug targets, such as hormone and neurotransmitter receptors.'' Aurora designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. Aurora is developing an integrated technology platform composed of a portfolio of proprietary fluorescent assay technologies and an ultra-high throughput screening system designed to allow assay miniaturization and to overcome many of the limitations associated with the traditional drug discovery process. The company believes that this platform will enable Aurora and its collaborators to take advantage of the opportunities created by recent advances in genomics and combinatorial chemistry that have generated many new therapeutic targets and an abundance of new, small molecule compounds. Current collaborators include Merck & Co., Warner-Lambert Co. [NYSE:WLA - news], Bristol-Myers Squibb, Eli Lilly and Co. [NYSE:LLY - news], Roche Bioscience, Sequana Therapeutics Inc. [Nasdaq:SQNA - news], and Allelix Biopharmaceuticals Inc.